<DOC>
	<DOC>NCT00004763</DOC>
	<brief_summary>OBJECTIVES: I. Evaluate the beneficial effects of leuprolide depot, oral contraceptive therapy, and leuprolide/oral contraceptive therapy in the management of patients with ovarian hyperandrogenism.</brief_summary>
	<brief_title>Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a randomized study. Patients are randomly assigned to a 6-month course of leuprolide versus ethinyl estradiol/norethindrone (Ovcon 35) versus leuprolide plus Ovcon 35. Leuprolide is administered intramuscularly in depot form every 28 days.</detailed_description>
	<mesh_term>Hyperandrogenism</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Mestranol</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination</mesh_term>
	<mesh_term>Norinyl</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Ovarian hyperandrogenism with Lorenzo hirsutism score 7 to 20, with or without severe acne Serum hormone levels: Folliclestimulating hormone no greater than 40 mIU/mL Luteinizing hormone no greater than 40 mIU/mL Testosterone 60 to 200 ng/dL Dehydroepiandrosterone sulfate no greater than 430 micrograms/dL 17hydroxyprogesterone no greater than 3.3 ng/mL in follicular phase Prolactin no greater than 18 ng/dL No adrenal or ovarian tumors Prior/Concurrent Therapy At least 6 months since exogenous steroids At least 48 hours since drugs other than acetaminophen, ibuprofen, and aspirin Patient Characteristics No malignancy, including the following carcinomas: Breast Cervix Ovary Uterus No other serious illness No cigarette smokers No nursing women No pregnancy within 6 months prior to entry</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>endocrine disorders</keyword>
	<keyword>hyperandrogenism</keyword>
	<keyword>rare disease</keyword>
</DOC>